Biotech · Public company · Waltham, MA, US
Dyne Therapeutics, Inc.
Ticker DYN · SEC CIK 0001818794
Track this companyFree. Adds Dyne Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials77 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline4
- zeleciment basivarsen (DYNE-101)Phase 3 · Myotonic Dystrophy Type 1 (DM1)ClinicalTrials.gov · fetched Nov 12, 2026
- Zeleciment Rostudirsen (DYNE-251)Phase 3 · Duchenne Muscular Dystrophy (DMD)ClinicalTrials.gov · fetched Nov 12, 2026
- DYNE-101Phase 2 · Myotonic Dystrophy Type 1 (DM1)ClinicalTrials.gov · fetched Nov 12, 2026
- DYNE-251Phase 2 · Duchenne Muscular Dystrophy (DMD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) ExtensionRECRUITING · started Oct 15, 2026ClinicalTrials.gov NCT07700225 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)PHASE3 · RECRUITING · started Jun 1, 2026ClinicalTrials.gov NCT07608432 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1PHASE3 · RECRUITING · started May 14, 2026ClinicalTrials.gov NCT07486934 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 5, 2022ClinicalTrials.gov NCT05481879 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 12, 2022ClinicalTrials.gov NCT05524883 · fetched Nov 12, 2026
- Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)RECRUITING · started Dec 15, 2020ClinicalTrials.gov NCT04635891 · fetched Nov 12, 2026
- Clinical Trial Readiness to Solve Barriers to Drug Development in FSHDACTIVE_NOT_RECRUITING · started Mar 5, 2018ClinicalTrials.gov NCT03458832 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026